BIOMARIN PHARMACEUTICAL INC (BMRN)
US09061G1013 - Common Stock
Overall BMRN gets a fundamental rating of 7 out of 10. We evaluated BMRN against 568 industry peers in the Biotechnology industry. BMRN scores excellent points on both the profitability and health parts. This is a solid base for a good stock. An interesting combination arises when we look at growth and value: BMRN is growing strongly while it also seems undervalued. This makes BMRN very considerable for value and growth and quality investing!
1. Profitability
1.1 Basic Checks
BMRN had positive earnings in the past year.
BMRN had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: BMRN reported negative net income in multiple years.
Each year in the past 5 years BMRN had a positive operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of 4.70%, BMRN belongs to the top of the industry, outperforming 94.69% of the companies in the same industry.
BMRN has a Return On Equity of 5.95%. This is amongst the best in the industry. BMRN outperforms 94.69% of its industry peers.
The Return On Invested Capital of BMRN (5.27%) is better than 94.87% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.7% | ||
| ROE | 5.95% | ||
| ROIC | 5.27% |
ROA(3y)1.2%
ROA(5y)3.56%
ROE(3y)1.65%
ROE(5y)5.02%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
BMRN has a Profit Margin of 11.71%. This is amongst the best in the industry. BMRN outperforms 95.58% of its industry peers.
BMRN's Profit Margin has declined in the last couple of years.
With an excellent Operating Margin value of 14.88%, BMRN belongs to the best of the industry, outperforming 95.93% of the companies in the same industry.
BMRN has a better Gross Margin (78.95%) than 86.55% of its industry peers.
In the last couple of years the Gross Margin of BMRN has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 14.88% | ||
| PM (TTM) | 11.71% | ||
| GM | 78.95% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-46.86%
PM growth 5YN/A
GM growth 3Y3.1%
GM growth 5Y-0.03%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so BMRN is destroying value.
Compared to 1 year ago, BMRN has more shares outstanding
The number of shares outstanding for BMRN has been increased compared to 5 years ago.
Compared to 1 year ago, BMRN has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 6.11 indicates that BMRN is not in any danger for bankruptcy at the moment.
The Altman-Z score of BMRN (6.11) is better than 82.65% of its industry peers.
BMRN has a debt to FCF ratio of 1.98. This is a very positive value and a sign of high solvency as it would only need 1.98 years to pay back of all of its debts.
BMRN has a better Debt to FCF ratio (1.98) than 95.22% of its industry peers.
A Debt/Equity ratio of 0.11 indicates that BMRN is not too dependend on debt financing.
BMRN has a worse Debt to Equity ratio (0.11) than 65.66% of its industry peers.
Although BMRN does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.11 | ||
| Debt/FCF | 1.98 | ||
| Altman-Z | 6.11 |
ROIC/WACC0.46
WACC11.48%
2.3 Liquidity
BMRN has a Current Ratio of 4.27. This indicates that BMRN is financially healthy and has no problem in meeting its short term obligations.
BMRN has a Current ratio of 4.27. This is comparable to the rest of the industry: BMRN outperforms 48.85% of its industry peers.
A Quick Ratio of 2.62 indicates that BMRN has no problem at all paying its short term obligations.
BMRN has a worse Quick ratio (2.62) than 68.32% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.27 | ||
| Quick Ratio | 2.62 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 127.27% over the past year.
Measured over the past years, BMRN shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -40.67% on average per year.
BMRN shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 19.14%.
The Revenue has been growing by 10.16% on average over the past years. This is quite good.
EPS 1Y (TTM)127.27%
EPS 3Y-40.67%
EPS 5YN/A
EPS Q2Q%161.9%
Revenue 1Y (TTM)19.14%
Revenue growth 3Y9.15%
Revenue growth 5Y10.16%
Sales Q2Q%28.28%
3.2 Future
BMRN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 47.29% yearly.
Based on estimates for the next years, BMRN will show a quite strong growth in Revenue. The Revenue will grow by 9.25% on average per year.
EPS Next Y120.5%
EPS Next 2Y79.23%
EPS Next 3Y62.26%
EPS Next 5Y47.29%
Revenue Next Year17.05%
Revenue Next 2Y13.38%
Revenue Next 3Y12.22%
Revenue Next 5Y9.25%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 37.52, the valuation of BMRN can be described as expensive.
Based on the Price/Earnings ratio, BMRN is valued cheaper than 94.34% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 27.73. BMRN is valued slightly more expensive when compared to this.
The Price/Forward Earnings ratio is 21.52, which indicates a rather expensive current valuation of BMRN.
Compared to the rest of the industry, the Price/Forward Earnings ratio of BMRN indicates a rather cheap valuation: BMRN is cheaper than 94.69% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.83. BMRN is around the same levels.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 37.52 | ||
| Fwd PE | 21.52 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, BMRN is valued cheaper than 95.04% of the companies in the same industry.
94.69% of the companies in the same industry are more expensive than BMRN, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 41.59 | ||
| EV/EBITDA | 22.41 |
4.3 Compensation for Growth
BMRN's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of BMRN may justify a higher PE ratio.
BMRN's earnings are expected to grow with 62.26% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.31
PEG (5Y)N/A
EPS Next 2Y79.23%
EPS Next 3Y62.26%
5. Dividend
5.1 Amount
No dividends for BMRN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BIOMARIN PHARMACEUTICAL INC
NASDAQ:BMRN (12/20/2024, 8:00:01 PM)
After market: 65.66 0 (0%)65.66
+0.66 (+1.02%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners101.09%
Inst Owner Change-1.62%
Ins Owners0.7%
Ins Owner Change0.54%
Market Cap12.51B
Analysts81.11
Price Target99.31 (51.25%)
Short Float %3.05%
Short Ratio3.9
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.72%
Min EPS beat(2)4.22%
Max EPS beat(2)57.23%
EPS beat(4)3
Avg EPS beat(4)16.93%
Min EPS beat(4)-24.46%
Max EPS beat(4)57.23%
EPS beat(8)6
Avg EPS beat(8)28.16%
EPS beat(12)9
Avg EPS beat(12)-8.43%
EPS beat(16)13
Avg EPS beat(16)29.42%
Revenue beat(2)2
Avg Revenue beat(2)4.93%
Min Revenue beat(2)4.42%
Max Revenue beat(2)5.44%
Revenue beat(4)2
Avg Revenue beat(4)1.73%
Min Revenue beat(4)-2.4%
Max Revenue beat(4)5.44%
Revenue beat(8)3
Avg Revenue beat(8)-0.1%
Revenue beat(12)5
Avg Revenue beat(12)-0.4%
Revenue beat(16)8
Avg Revenue beat(16)0.27%
PT rev (1m)-3.9%
PT rev (3m)-11%
EPS NQ rev (1m)0%
EPS NQ rev (3m)8.71%
EPS NY rev (1m)0%
EPS NY rev (3m)0.68%
Revenue NQ rev (1m)0.2%
Revenue NQ rev (3m)-3.34%
Revenue NY rev (1m)0.17%
Revenue NY rev (3m)0.7%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 37.52 | ||
| Fwd PE | 21.52 | ||
| P/S | 4.55 | ||
| P/FCF | 41.59 | ||
| P/OCF | 30.18 | ||
| P/B | 2.31 | ||
| P/tB | 2.52 | ||
| EV/EBITDA | 22.41 |
EPS(TTM)1.75
EY2.67%
EPS(NY)3.05
Fwd EY4.65%
FCF(TTM)1.58
FCFY2.4%
OCF(TTM)2.18
OCFY3.31%
SpS14.44
BVpS28.4
TBVpS26.01
PEG (NY)0.31
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.7% | ||
| ROE | 5.95% | ||
| ROCE | 6.68% | ||
| ROIC | 5.27% | ||
| ROICexc | 6.22% | ||
| ROICexgc | 6.81% | ||
| OM | 14.88% | ||
| PM (TTM) | 11.71% | ||
| GM | 78.95% | ||
| FCFM | 10.93% |
ROA(3y)1.2%
ROA(5y)3.56%
ROE(3y)1.65%
ROE(5y)5.02%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-46.86%
PM growth 5YN/A
GM growth 3Y3.1%
GM growth 5Y-0.03%
F-Score8
Asset Turnover0.4
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.11 | ||
| Debt/FCF | 1.98 | ||
| Debt/EBITDA | 1.17 | ||
| Cap/Depr | 114.17% | ||
| Cap/Sales | 4.14% | ||
| Interest Coverage | 39.55 | ||
| Cash Conversion | 81.42% | ||
| Profit Quality | 93.35% | ||
| Current Ratio | 4.27 | ||
| Quick Ratio | 2.62 | ||
| Altman-Z | 6.11 |
F-Score8
WACC11.48%
ROIC/WACC0.46
Cap/Depr(3y)114.13%
Cap/Depr(5y)125.65%
Cap/Sales(3y)5.73%
Cap/Sales(5y)6.83%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)127.27%
EPS 3Y-40.67%
EPS 5YN/A
EPS Q2Q%161.9%
EPS Next Y120.5%
EPS Next 2Y79.23%
EPS Next 3Y62.26%
EPS Next 5Y47.29%
Revenue 1Y (TTM)19.14%
Revenue growth 3Y9.15%
Revenue growth 5Y10.16%
Sales Q2Q%28.28%
Revenue Next Year17.05%
Revenue Next 2Y13.38%
Revenue Next 3Y12.22%
Revenue Next 5Y9.25%
EBIT growth 1Y243.03%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year193.21%
EBIT Next 3Y78.73%
EBIT Next 5Y46.56%
FCF growth 1Y639.17%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y130.12%
OCF growth 3Y23.09%
OCF growth 5Y51.13%